Tag: ADC

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


targeted14

Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymp...

Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.

Visit website
Onclive17

Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...

High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
onclive5

Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma

  Feb 24 2021 Tagged Abs, CAR-T, BiTE, ADC, MM

Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.

Visit website
Multiple6

HDP-101, an antibody-targeted amanitin conjugate to advance to phase I/IIa testi...

  Feb 17 2021 Tagged Abs, ADC, MM, anti-BCMA

The U.S. Food and Drug Administration (FDA) has announced that the B-cell maturation antigen (BCMA) antibody–drug conjugate HDP-101 can proceed to phase I/IIa testing.

Visit website
VJhemonic15

First-in-human trial of an anti-BCMA ADC for R/R myeloma

  Feb 03 2021 Tagged MM, ADC, anti-BCMA

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.

Visit website